/
We are a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of our company is built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry.
17.89% operating margin is respectable but not wide. ROIC at 8.37%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$43M
▲ +132.1% YoY
Op. Margin
17.89%
ROIC
-30.47%
▲ +58.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$34M
▲ +147.5% YoY
Op. Cash Flow (TTM)
-$34M
▲ +147.5% YoY
Net Debt
-$100M
Net Cash Position
Cash & Equiv.
$118M
Continue Research